Zenta Walther

Medical Genetics

789 Howard Ave
New Haven, CT 6519.

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Commercial price variation in precision oncology testing across US hospitals.

Commercial price variation in precision oncology testing across US hospitals.

Journal: Health affairs scholar

Published: June 17, 2026

Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

Journal: Nature

Published: February 27, 2025

A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial.

A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 26, 2024

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

Journal: Nature

Published: October 27, 2023

A destabilizing Y891D mutation in activated EGFR impairs sensitivity to kinase inhibition.

A destabilizing Y891D mutation in activated EGFR impairs sensitivity to kinase inhibition.

Journal: NPJ precision oncology

Published: August 10, 2023

Platinum Sensitivity in IDH1/2 Mutated Intrahepatic Cholangiocarcinoma: Not All "BRCAness" Is Created Equal.

Platinum Sensitivity in IDH1/2 Mutated Intrahepatic Cholangiocarcinoma: Not All "BRCAness" Is Created Equal.

Journal: Cancer investigation

Published: July 28, 2023

Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer.

Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: April 17, 2023

ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts.

ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts.

Journal: Cancer research

Published: March 09, 2023

NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors.

NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors.

Journal: Cancer research communications

Published: January 05, 2023

Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations.

Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 15, 2022

Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations.

Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations.

Journal: Nature communications

Published: May 31, 2022

Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403).

Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403).

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 08, 2022

Showing 1-12 of 30

Last Updated: 09/26/2026